富维斯特朗
医学
肿瘤科
内科学
转移性乳腺癌
帕博西利布
细胞周期蛋白依赖激酶4
乳腺癌
癌症
激素受体
癌症研究
雌激素受体
细胞周期
细胞周期蛋白依赖激酶2
作者
Kevin Kalinsky,Giampaolo Bianchini,Erika Hamilton,Stephanie L. Graff,Stephanie L. Graff,Rinath Jeselsohn,Miguel Martín,Rachel M. Layman,Sara A. Hurvitz,Sarah Sammons,Peter A. Kaufman,Montserrat Muñoz,Jiun‐I Lai,Holly Knoderer,Cynthia Sandoval,Aarti Chawla,Bastien Nguyen,Yanhong Zhou,Elizabeth E. Ravenberg,Lacey M. Litchfield,Lillian M. Smyth,Seth A. Wander
摘要
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i.
科研通智能强力驱动
Strongly Powered by AbleSci AI